MedPath

A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation

Completed
Conditions
Erectile Dysfunction
Interventions
Behavioral: No intervention
Registration Number
NCT00210678
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Brief Summary

The purpose of the study is to characterize intravaginal ejaculatory latency time (time between the start of vaginal intercourse and the start of intravaginal ejaculation) in men with and without premature ejaculation (PE) and to assess the validity of patient-reported outcomes.

Detailed Description

This is a multinational, multicenter, observational study in men with and without PE. The study consists of three visits: one visit for screening and enrollment, and two visits for observation after 1 and 2 months (total duration of 8 weeks). No study treatment for PE is administered to patients during the course of the study. Patients and their partners are expected to attempt sexual intercourse at least 2 times a week during the 8-week study period and to use a stopwatch to record the intravaginal ejaculatory latency time (IELT) during intercourse. At visits during the observation period "patients" (and/or partners if partners are responsible for completing questionaires) also provide patient-reported outcomes (PROs) by answering several questionnaires that include the topics of control over ejaculation, satisfaction with sexual intercourse, personal distress, interpersonal difficulty, and self-esteem. The study will estimate the distribution of the average IELT values for men with PE and men without PE.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
1115
Inclusion Criteria
  • Must be in a stable, monogamous, sexual relationship with the same woman (18 years of age or older) for at least 6 months, who plan to maintain their relationship for the duration of the study
  • Must be in good general health
  • Patient and partner willing to avoid situations or activities that may have an effect on their sexual activity (eg, refrain from any preplanned surgery)
Exclusion Criteria
  • Has history of drug abuse within the past 2 years
  • Has history of or current major psychiatric disorder such as mood disorders, anxiety disorders, schizophrenia, other psychotic disorders, or alcoholism
  • Must have erectile dysfunction
  • Patient who has decreased interest in sexual intercourse or has other forms of sexual dysfunction
  • Patient whose partner has decreased interest in sexual intercourse, painful intercourse, or other forms of female sexual dysfunction
  • Patient whose partner is more than 3 months pregnant

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Group: 2No interventionMen without PE
Group: 1No interventionMen with premature ejaculation (PE)
Primary Outcome Measures
NameTimeMethod
Change in Intravaginal Ejaculatory Latency Time (IELT)Day 1 to Week 8

Estimated distribution of the average IELT for both the premature ejaculation (PE) and non-PE populations will be calculated.

Change in Patient-Reported Outcomes (PRO)Week 4 and Week 8

Additional evidence of reliability and validity of PROs for patients with and without PE and their partners will be expolred. The PROs will include different parameters related to (control over ejaculation, satisfaction with sexual intercourse, personal distress, and interpersonal difficulty).

Secondary Outcome Measures
NameTimeMethod
PROs and IELT as indicators to clasify PE status.Up to Week 8

The study will evaluate the ability of PROs and IELT to classify PE status

Association between intravaginal ejaculatory latency time (IELT) and patient reportedout comes (PROs)Up to Week 8

Association between IELT and PROs used in this study will be explored.

Utility of the Male Sexual Function Scale and Ejaculation QuestionnairesDay 1

The study will explore utility of the Male Sexual Function Scale and Ejaculation Questionnaire as screening instruments.

© Copyright 2025. All Rights Reserved by MedPath